SAN FRANCISCO--- FibroGen Appoints K. Peony Yu, M.D., Vice President, Clinical Development
FibroGen, Inc. today announced the appointment of K. Peony Yu, M.D., as Vice President, Clinical Development. Dr. Yu brings to FibroGen expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the US and EU, as well as experience with successful leadership of clinical teams.
Dr. Yu was most recently Vice President, Clinical Research, at Anesiva, Inc. where she was responsible for management of clinical research, statistics/data management, clinical operations, and medical affairs/medical information for all clinical programs, including the late-stage clinical development and approval of Zingo , a drug-device combination for pain management. Prior to Anesiva, Dr. Yu was Director, Clinical Development, at ALZA Corporation (a subsidiary of Johnson & Johnson) where she was Global Clinical Lead for IONSYS, a drug-device combination for post-operative pain, and led a successful New Drug Application resubmission with the U.S. Food & Drug Administration and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc., and at Elan Pharmaceuticals.
“Peony’s experience in leading multifunctional clinical teams with proven success in advancing investigational products through all stages of clinical development through regulatory approval will be an important asset to FibroGen,” said Frank H. Valone, M.D., Chief Medical Officer of FibroGen. “We look forward to her leadership of our multiple clinical programs in the U.S. and globally.”
Dr. Yu received a B.S. in Chemical Engineering and an M.D. both from the University of California, Davis, followed by residency training at Stanford Medical School.
About FibroGen
FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, conditions associated with tissue damage or injury, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen's proprietary cosmetic dermal filler and biomaterials supply business.
For more information about FibroGen, Inc., please visit www.fibrogen.com.